BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 30608252)

  • 1. Treatment of diabetes and heart failure: a paradigm shift for cardiologists?
    Brochu B; Chan M
    Curr Opin Cardiol; 2019 Mar; 34(2):207-212. PubMed ID: 30608252
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EMPA-REG and Other Cardiovascular Outcome Trials of Glucose-lowering Agents: Implications for Future Treatment Strategies in Type 2 Diabetes Mellitus.
    Schernthaner G; Schernthaner-Reiter MH; Schernthaner GH
    Clin Ther; 2016 Jun; 38(6):1288-1298. PubMed ID: 27210264
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advances in type 2 diabetes therapy: a focus on cardiovascular and renal outcomes.
    Libianto R; Davis TM; Ekinci EI
    Med J Aust; 2020 Feb; 212(3):133-139. PubMed ID: 31910303
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of Diabetes in Patients with Heart Failure.
    Bowes CD; Lien LF; Butler J
    Curr Cardiol Rep; 2018 Aug; 20(10):97. PubMed ID: 30151728
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of New Glucose-Lowering Drugs on Risk of Heart Failure in Type 2 Diabetes: A Network Meta-Analysis.
    Kramer CK; Ye C; Campbell S; Retnakaran R
    JACC Heart Fail; 2018 Oct; 6(10):823-830. PubMed ID: 30196071
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of Heart Failure in Diabetes Cardiovascular Outcomes Trials: Is What We Are Currently Capturing Adequate?
    Bowes CD; Lien LF; Butler J
    Curr Diab Rep; 2019 May; 19(7):39. PubMed ID: 31127397
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Novel antidiabetic drugs and cardiovascular complications].
    Pareek M; Mortensen MB; Løfgren B; Nielsen ML; Olsen MH; Andersen NH
    Ugeskr Laeger; 2018 Feb; 180(6):. PubMed ID: 29429477
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New Agents for the Treatment of Type 2 Diabetes.
    Libianto R; Ekinci EI
    Crit Care Clin; 2019 Apr; 35(2):315-328. PubMed ID: 30784612
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical implications of cardiovascular outcome trials in type 2 diabetes.
    Mellbin LG; Wang A; Rydén L
    Herz; 2019 May; 44(3):192-202. PubMed ID: 30805659
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Not Available].
    Toft E; Rydén M
    Lakartidningen; 2018 Feb; 115():. PubMed ID: 29461566
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiovascular safety outcomes of new antidiabetic therapies.
    LeBras MH; Barry AR; Koshman SL
    Am J Health Syst Pharm; 2017 Jul; 74(13):970-976. PubMed ID: 28483748
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [A revolution in the management of type 2 diabetes : antidiabetic agents providing a cardiovascular and renal protection independently of glucose control !].
    Scheen AJ; Paquot N
    Rev Med Liege; 2020 May; 75(5-6):392-398. PubMed ID: 32496686
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative outcomes of heart failure among existent classes of anti-diabetic agents: a network meta-analysis of 171,253 participants from 91 randomized controlled trials.
    Yang DY; He X; Liang HW; Zhang SZ; Zhong XB; Luo CF; Du ZM; He JG; Zhuang XD; Liao XX
    Cardiovasc Diabetol; 2019 Apr; 18(1):47. PubMed ID: 30961600
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Making sense of newer treatment options for type 2 diabetes.
    Lee PC; Hare MJL; Bach LA
    Intern Med J; 2018 Jul; 48(7):762-769. PubMed ID: 29984503
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Cardiovascular aspects of diabetes treatment : Finally a reason for cardiologists to be pleased].
    Forst T; Plum-Mörschel L; Weber MM
    Internist (Berl); 2017 Mar; 58(3):293-302. PubMed ID: 28120022
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treating Diabetes in Patients with Heart Failure: Moving from Risk to Benefit.
    DeFilippis EM; Givertz MM
    Curr Heart Fail Rep; 2016 Jun; 13(3):111-8. PubMed ID: 27188181
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiovascular benefits and safety of non-insulin medications used in the treatment of type 2 diabetes mellitus.
    Yandrapalli S; Jolly G; Horblitt A; Sanaani A; Aronow WS
    Postgrad Med; 2017 Nov; 129(8):811-821. PubMed ID: 28749197
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Contrasting effects on the risk of macrovascular and microvascular events of antihyperglycemic drugs that enhance sodium excretion and lower blood pressure.
    Packer M
    Diabet Med; 2018 Jun; 35(6):707-713. PubMed ID: 29532519
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diabetes medications and cardiovascular disease: at long last progress.
    Lupsa BC; Inzucchi SE
    Curr Opin Endocrinol Diabetes Obes; 2018 Apr; 25(2):87-93. PubMed ID: 29369916
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Toxicology of Medications for Diabetes Mellitus.
    Baumgartner K; Devgun J
    Crit Care Clin; 2021 Jul; 37(3):577-589. PubMed ID: 34053707
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.